Geroscience Drugs & Trials

This field tracks drugs and compounds designed to act on the biological pathways involved in aging itself, rather than treating one disease at a time. It also tracks how far those candidates have progressed through testing in people.

If a drug can safely act on one or more aging pathways in humans, it could delay the onset of multiple age-related conditions at once instead of treating them separately. Clinical trial progress is one of the clearest signals of whether these ideas hold up outside the laboratory.

Progress of this kind would support the broader goal of Longevity Escape Velocity: reaching a point where advances across multiple medical fields extend healthy lifespan faster than time passes.

• Human trials: Clinical trials of compounds designed to act on aging-related pathways.
• Trial progression: Movement through trial phases, including reported functional or biomarker endpoints.
• Drug repurposing: Studies that test existing drugs against aging-related pathways.
• Regulatory milestones: Steps toward treating aging itself as a recognized target, rather than a single disease.

• Preclinical or animal-only results presented as if they were human findings.
• Anecdotal reports from individual users.
• Trial announcements that provide no reported results.

• Regulation: Most regulators do not yet recognize aging itself as an approvable treatment target.
• Trial duration: Observing aging-related endpoints often requires long studies.
• Funding: Large, long-term human trials remain expensive and difficult to finance.
• Signal versus noise: Distinguishing a drug’s effect from natural variation between people remains difficult.

Lowest score of the eight and the slowest backcast growth. Rapamycin, metformin, acarbose and the GLP-1 class have large human exposure, but healthspan effect sizes are modest and inferred from disease endpoints rather than aging endpoints. The bottleneck is not chemistry, it is trial design, duration and ownership: a properly powered aging-endpoint trial takes years and no sponsor owns the indication. Twenty years of slow movement is itself the evidence.

This assessment does not predict whether any specific geroscience drug will be approved or prove effective in the real world. Trial progress is a signal of visible momentum, not a guarantee of success.

It should be treated as an evolving signal, not a clinical forecast or guaranteed roadmap.